- Home
- IPHA vs CCCC Comparison
IPHA vs CCCC Comparison
Compare IPHA & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IPHA | CCCC |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.6M | 194.8M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IPHA | CCCC |
|---|---|---|
| Price | $1.71 | $1.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $5.00 | ★ $7.25 |
| AVG Volume (30 Days) | 18.3K | ★ 1.5M |
| Earning Date | 03-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $14,839,695.00 | ★ $30,108,000.00 |
| Revenue This Year | $22.29 | N/A |
| Revenue Next Year | $43.90 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.63 | $1.09 |
| 52 Week High | $2.63 | $3.72 |
Technical Indicators
Market Signals| Indicator | IPHA | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 37.04 |
| Support Level | N/A | $1.69 |
| Resistance Level | N/A | $2.04 |
| Average True Range (ATR) | 0.00 | 0.12 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 0.00 | 14.80 |
Price Performance
Historical ComparisonAbout IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.